Loading…

Inhibition of friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action

We developed a syngeneic mouse IgG2a monoclonal antibody (MAb) A9D41 directed against the Friend leukemia virus envelope gp70 antigen present on the cell surface membranes of virus producer 3C18 Friend leukemia cells (FLC). A9D41 showed a marked antitumor activity in DBA/2 mice given injections of g...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1992-05, Vol.52 (10), p.2880-2889
Main Authors: SALA, A, GRESSER, I, CHASSOUX, D.D, MAURY, C, SANTODONATO, L, EID, P, MAUNOURY, M.-T, BARCA, SS, CIANFRIGLIA, M, BELARDELLI, F
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 2889
container_issue 10
container_start_page 2880
container_title Cancer research (Chicago, Ill.)
container_volume 52
creator SALA, A
GRESSER, I
CHASSOUX, D.D
MAURY, C
SANTODONATO, L
EID, P
MAUNOURY, M.-T
BARCA, SS
CIANFRIGLIA, M
BELARDELLI, F
description We developed a syngeneic mouse IgG2a monoclonal antibody (MAb) A9D41 directed against the Friend leukemia virus envelope gp70 antigen present on the cell surface membranes of virus producer 3C18 Friend leukemia cells (FLC). A9D41 showed a marked antitumor activity in DBA/2 mice given injections of gp70 positive 3C18 FLC, but it was ineffective in mice given injections of gp70 negative 745 FLC or unrelated tumor cells. A9D41 was particularly effective in inhibiting the development of 3C18 FLC liver and spleen metastases. MAb was also effective as adjuvant therapy in inhibiting visceral metastases after excision of an established s.c. FLC tumor, and combined therapy of A9D41 with mouse interferon alpha/beta was more effective than MAb or interferon alpha/beta alone. The immune system of the host played a decisive role in the antimetastatic action of A9D41. Thus, although MAb was cytotoxic for 3C18 FLC in vitro in the presence of rabbit complement, the F(ab')2 fragment was ineffective in vivo, and the antitumor effect of MAb was abolished in mice treated with an antibody to CD4 and diminished in natural killer cell-deficient beige and athymic nude mice. MAb-treated mice surviving injection of FLC developed an immune response to 3C18 FLC.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72933730</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72933730</sourcerecordid><originalsourceid>FETCH-LOGICAL-h271t-3c72fad4574913b22d86a1c3a45ef6b383b852b4563f9ceeea38bdbe12afc8f43</originalsourceid><addsrcrecordid>eNo9kN1KxDAQhYso67r6CEIuxLtCkzRt91IWfxYWvNHrMkknNJqftUmVfQZf2i5WYWCY-Q6HM3OSLangTV6XpTjNlkVRNLkoa3aeXcT4No2CFmKRLaho6Lrgy-x763sjTTLBk6CJHgz6jlgc39EZIAqtJZ8mKhzAEocJ4lQYiTwQIB6_iAs-KBv8hMEnI0M3kcliCBaPjqlHYpwbPZJ4iAnd37IPMRHjiUmRgDoGuMzONNiIV3NfZa8P9y-bp3z3_Ljd3O3yntU05VzVTENXirpcUy4Z65oKqOJQCtSV5A2XjWCyFBXXa4WIwBvZSaQMtGp0yVfZ7a_vfggfI8bUuuOF1oLHMMa2ZmvOa15MwutZOEqHXbsfjIPh0M7fm_jNzCEqsHoAr0z8lwnOBK0q_gP3g3vN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72933730</pqid></control><display><type>article</type><title>Inhibition of friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action</title><source>EZB Electronic Journals Library</source><creator>SALA, A ; GRESSER, I ; CHASSOUX, D.D ; MAURY, C ; SANTODONATO, L ; EID, P ; MAUNOURY, M.-T ; BARCA, SS ; CIANFRIGLIA, M ; BELARDELLI, F</creator><creatorcontrib>SALA, A ; GRESSER, I ; CHASSOUX, D.D ; MAURY, C ; SANTODONATO, L ; EID, P ; MAUNOURY, M.-T ; BARCA, SS ; CIANFRIGLIA, M ; BELARDELLI, F</creatorcontrib><description>We developed a syngeneic mouse IgG2a monoclonal antibody (MAb) A9D41 directed against the Friend leukemia virus envelope gp70 antigen present on the cell surface membranes of virus producer 3C18 Friend leukemia cells (FLC). A9D41 showed a marked antitumor activity in DBA/2 mice given injections of gp70 positive 3C18 FLC, but it was ineffective in mice given injections of gp70 negative 745 FLC or unrelated tumor cells. A9D41 was particularly effective in inhibiting the development of 3C18 FLC liver and spleen metastases. MAb was also effective as adjuvant therapy in inhibiting visceral metastases after excision of an established s.c. FLC tumor, and combined therapy of A9D41 with mouse interferon alpha/beta was more effective than MAb or interferon alpha/beta alone. The immune system of the host played a decisive role in the antimetastatic action of A9D41. Thus, although MAb was cytotoxic for 3C18 FLC in vitro in the presence of rabbit complement, the F(ab')2 fragment was ineffective in vivo, and the antitumor effect of MAb was abolished in mice treated with an antibody to CD4 and diminished in natural killer cell-deficient beige and athymic nude mice. MAb-treated mice surviving injection of FLC developed an immune response to 3C18 FLC.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 1581903</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Animals ; Antibodies, Monoclonal - therapeutic use ; Antibody Formation - immunology ; Antigens, Neoplasm - immunology ; Antigens, Surface - immunology ; Antineoplastic agents ; Biological and medical sciences ; Cell Division - physiology ; Combined Modality Therapy ; Complement System Proteins - immunology ; Cytotoxicity, Immunologic ; Friend murine leukemia virus - immunology ; Immunotherapy ; Injections, Intravenous ; Interferon-alpha - pharmacology ; Interferon-beta - pharmacology ; Leukemia, Erythroblastic, Acute - immunology ; Leukemia, Erythroblastic, Acute - pathology ; Leukemia, Erythroblastic, Acute - therapy ; Liver Neoplasms - prevention &amp; control ; Liver Neoplasms - secondary ; Male ; Medical sciences ; Mice ; Mice, Inbred DBA ; Neoplasm Metastasis - immunology ; Neoplasm Metastasis - prevention &amp; control ; Neoplasm Transplantation ; Pharmacology. Drug treatments ; Splenic Neoplasms - prevention &amp; control ; Splenic Neoplasms - secondary ; Tumor Cells, Cultured</subject><ispartof>Cancer research (Chicago, Ill.), 1992-05, Vol.52 (10), p.2880-2889</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=5325166$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1581903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SALA, A</creatorcontrib><creatorcontrib>GRESSER, I</creatorcontrib><creatorcontrib>CHASSOUX, D.D</creatorcontrib><creatorcontrib>MAURY, C</creatorcontrib><creatorcontrib>SANTODONATO, L</creatorcontrib><creatorcontrib>EID, P</creatorcontrib><creatorcontrib>MAUNOURY, M.-T</creatorcontrib><creatorcontrib>BARCA, SS</creatorcontrib><creatorcontrib>CIANFRIGLIA, M</creatorcontrib><creatorcontrib>BELARDELLI, F</creatorcontrib><title>Inhibition of friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>We developed a syngeneic mouse IgG2a monoclonal antibody (MAb) A9D41 directed against the Friend leukemia virus envelope gp70 antigen present on the cell surface membranes of virus producer 3C18 Friend leukemia cells (FLC). A9D41 showed a marked antitumor activity in DBA/2 mice given injections of gp70 positive 3C18 FLC, but it was ineffective in mice given injections of gp70 negative 745 FLC or unrelated tumor cells. A9D41 was particularly effective in inhibiting the development of 3C18 FLC liver and spleen metastases. MAb was also effective as adjuvant therapy in inhibiting visceral metastases after excision of an established s.c. FLC tumor, and combined therapy of A9D41 with mouse interferon alpha/beta was more effective than MAb or interferon alpha/beta alone. The immune system of the host played a decisive role in the antimetastatic action of A9D41. Thus, although MAb was cytotoxic for 3C18 FLC in vitro in the presence of rabbit complement, the F(ab')2 fragment was ineffective in vivo, and the antitumor effect of MAb was abolished in mice treated with an antibody to CD4 and diminished in natural killer cell-deficient beige and athymic nude mice. MAb-treated mice surviving injection of FLC developed an immune response to 3C18 FLC.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibody Formation - immunology</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Antigens, Surface - immunology</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cell Division - physiology</subject><subject>Combined Modality Therapy</subject><subject>Complement System Proteins - immunology</subject><subject>Cytotoxicity, Immunologic</subject><subject>Friend murine leukemia virus - immunology</subject><subject>Immunotherapy</subject><subject>Injections, Intravenous</subject><subject>Interferon-alpha - pharmacology</subject><subject>Interferon-beta - pharmacology</subject><subject>Leukemia, Erythroblastic, Acute - immunology</subject><subject>Leukemia, Erythroblastic, Acute - pathology</subject><subject>Leukemia, Erythroblastic, Acute - therapy</subject><subject>Liver Neoplasms - prevention &amp; control</subject><subject>Liver Neoplasms - secondary</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred DBA</subject><subject>Neoplasm Metastasis - immunology</subject><subject>Neoplasm Metastasis - prevention &amp; control</subject><subject>Neoplasm Transplantation</subject><subject>Pharmacology. Drug treatments</subject><subject>Splenic Neoplasms - prevention &amp; control</subject><subject>Splenic Neoplasms - secondary</subject><subject>Tumor Cells, Cultured</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNo9kN1KxDAQhYso67r6CEIuxLtCkzRt91IWfxYWvNHrMkknNJqftUmVfQZf2i5WYWCY-Q6HM3OSLangTV6XpTjNlkVRNLkoa3aeXcT4No2CFmKRLaho6Lrgy-x763sjTTLBk6CJHgz6jlgc39EZIAqtJZ8mKhzAEocJ4lQYiTwQIB6_iAs-KBv8hMEnI0M3kcliCBaPjqlHYpwbPZJ4iAnd37IPMRHjiUmRgDoGuMzONNiIV3NfZa8P9y-bp3z3_Ljd3O3yntU05VzVTENXirpcUy4Z65oKqOJQCtSV5A2XjWCyFBXXa4WIwBvZSaQMtGp0yVfZ7a_vfggfI8bUuuOF1oLHMMa2ZmvOa15MwutZOEqHXbsfjIPh0M7fm_jNzCEqsHoAr0z8lwnOBK0q_gP3g3vN</recordid><startdate>19920515</startdate><enddate>19920515</enddate><creator>SALA, A</creator><creator>GRESSER, I</creator><creator>CHASSOUX, D.D</creator><creator>MAURY, C</creator><creator>SANTODONATO, L</creator><creator>EID, P</creator><creator>MAUNOURY, M.-T</creator><creator>BARCA, SS</creator><creator>CIANFRIGLIA, M</creator><creator>BELARDELLI, F</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19920515</creationdate><title>Inhibition of friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action</title><author>SALA, A ; GRESSER, I ; CHASSOUX, D.D ; MAURY, C ; SANTODONATO, L ; EID, P ; MAUNOURY, M.-T ; BARCA, SS ; CIANFRIGLIA, M ; BELARDELLI, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h271t-3c72fad4574913b22d86a1c3a45ef6b383b852b4563f9ceeea38bdbe12afc8f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibody Formation - immunology</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Antigens, Surface - immunology</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cell Division - physiology</topic><topic>Combined Modality Therapy</topic><topic>Complement System Proteins - immunology</topic><topic>Cytotoxicity, Immunologic</topic><topic>Friend murine leukemia virus - immunology</topic><topic>Immunotherapy</topic><topic>Injections, Intravenous</topic><topic>Interferon-alpha - pharmacology</topic><topic>Interferon-beta - pharmacology</topic><topic>Leukemia, Erythroblastic, Acute - immunology</topic><topic>Leukemia, Erythroblastic, Acute - pathology</topic><topic>Leukemia, Erythroblastic, Acute - therapy</topic><topic>Liver Neoplasms - prevention &amp; control</topic><topic>Liver Neoplasms - secondary</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred DBA</topic><topic>Neoplasm Metastasis - immunology</topic><topic>Neoplasm Metastasis - prevention &amp; control</topic><topic>Neoplasm Transplantation</topic><topic>Pharmacology. Drug treatments</topic><topic>Splenic Neoplasms - prevention &amp; control</topic><topic>Splenic Neoplasms - secondary</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SALA, A</creatorcontrib><creatorcontrib>GRESSER, I</creatorcontrib><creatorcontrib>CHASSOUX, D.D</creatorcontrib><creatorcontrib>MAURY, C</creatorcontrib><creatorcontrib>SANTODONATO, L</creatorcontrib><creatorcontrib>EID, P</creatorcontrib><creatorcontrib>MAUNOURY, M.-T</creatorcontrib><creatorcontrib>BARCA, SS</creatorcontrib><creatorcontrib>CIANFRIGLIA, M</creatorcontrib><creatorcontrib>BELARDELLI, F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SALA, A</au><au>GRESSER, I</au><au>CHASSOUX, D.D</au><au>MAURY, C</au><au>SANTODONATO, L</au><au>EID, P</au><au>MAUNOURY, M.-T</au><au>BARCA, SS</au><au>CIANFRIGLIA, M</au><au>BELARDELLI, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1992-05-15</date><risdate>1992</risdate><volume>52</volume><issue>10</issue><spage>2880</spage><epage>2889</epage><pages>2880-2889</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>We developed a syngeneic mouse IgG2a monoclonal antibody (MAb) A9D41 directed against the Friend leukemia virus envelope gp70 antigen present on the cell surface membranes of virus producer 3C18 Friend leukemia cells (FLC). A9D41 showed a marked antitumor activity in DBA/2 mice given injections of gp70 positive 3C18 FLC, but it was ineffective in mice given injections of gp70 negative 745 FLC or unrelated tumor cells. A9D41 was particularly effective in inhibiting the development of 3C18 FLC liver and spleen metastases. MAb was also effective as adjuvant therapy in inhibiting visceral metastases after excision of an established s.c. FLC tumor, and combined therapy of A9D41 with mouse interferon alpha/beta was more effective than MAb or interferon alpha/beta alone. The immune system of the host played a decisive role in the antimetastatic action of A9D41. Thus, although MAb was cytotoxic for 3C18 FLC in vitro in the presence of rabbit complement, the F(ab')2 fragment was ineffective in vivo, and the antitumor effect of MAb was abolished in mice treated with an antibody to CD4 and diminished in natural killer cell-deficient beige and athymic nude mice. MAb-treated mice surviving injection of FLC developed an immune response to 3C18 FLC.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>1581903</pmid><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 1992-05, Vol.52 (10), p.2880-2889
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_72933730
source EZB Electronic Journals Library
subjects Animals
Antibodies, Monoclonal - therapeutic use
Antibody Formation - immunology
Antigens, Neoplasm - immunology
Antigens, Surface - immunology
Antineoplastic agents
Biological and medical sciences
Cell Division - physiology
Combined Modality Therapy
Complement System Proteins - immunology
Cytotoxicity, Immunologic
Friend murine leukemia virus - immunology
Immunotherapy
Injections, Intravenous
Interferon-alpha - pharmacology
Interferon-beta - pharmacology
Leukemia, Erythroblastic, Acute - immunology
Leukemia, Erythroblastic, Acute - pathology
Leukemia, Erythroblastic, Acute - therapy
Liver Neoplasms - prevention & control
Liver Neoplasms - secondary
Male
Medical sciences
Mice
Mice, Inbred DBA
Neoplasm Metastasis - immunology
Neoplasm Metastasis - prevention & control
Neoplasm Transplantation
Pharmacology. Drug treatments
Splenic Neoplasms - prevention & control
Splenic Neoplasms - secondary
Tumor Cells, Cultured
title Inhibition of friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A22%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20friend%20leukemia%20cell%20visceral%20metastases%20by%20a%20new%20monoclonal%20antibody%20and%20role%20of%20the%20immune%20system%20of%20the%20host%20in%20its%20action&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=SALA,%20A&rft.date=1992-05-15&rft.volume=52&rft.issue=10&rft.spage=2880&rft.epage=2889&rft.pages=2880-2889&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E72933730%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h271t-3c72fad4574913b22d86a1c3a45ef6b383b852b4563f9ceeea38bdbe12afc8f43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72933730&rft_id=info:pmid/1581903&rfr_iscdi=true